Senior Correspondent, London
Ben's Feed
Apr 23, 2014
Apr 22, 2014
Apr 21, 2014
Apr 21, 2014

AstraZeneca cancer pipeline seen as draw for Pfizer

LONDON, April 21 (Reuters) – Pfizer may come back to
bid for British drug company AstraZeneca after its
reported 60 billion pound ($101 billion) takeover approach was
rejected, since a deal could make sense for the U.S.
pharmaceuticals giant as it seeks to build up its cancer
franchise.

In addition to adding promising – though still risky -
experimental medicines known as immunotherapies that boost the
body’s immune system to fight tumours, acquiring AstraZeneca
could also generate significant cost savings, according to
industry analysts.

Apr 20, 2014
Apr 17, 2014
Apr 17, 2014
Apr 17, 2014

GSK, facing bribery claims, battles to build new sales model

LONDON (Reuters) – Drugmaker GlaxoSmithKline (GSK.L: Quote, Profile, Research, Stock Buzz) – hit by bribery claims in five countries – is to employ hundreds more doctors as members of staff as it seeks to build a new sales model designed to eliminate sharp marketing practices.

Following a decision to cut commercial ties with outside doctors, GSK expects to increase its in-house team of physicians by 10-20 percent over the next year or so from around 1,500 at present, Chief Medical Officer James Shannon told Reuters.

Apr 17, 2014
Apr 17, 2014
    • About Ben

      "Ben Hirschler is European pharmaceuticals, biotechnology and healthcare correspondent, based in London. Previously, he was in charge of British company news and before that was posted to Johannesburg, covering the economic challenges facing post-apartheid South Africa."
    • More from Ben

    • Follow Ben